Companies /Healthcare

Ultragenyx Pharmaceutical Inc

NASDAQ: RARE Biotechnology
$16.30
▲ $0.20 (+1.24%) today
Markets closed · 4:44pm ET
24/7 Rating BUY
Our 12-month price target
$31.32
+94.5% upside by Nov 2027
Price when calculated $16.10 Nov 2, 2026
Street consensus $26.25 20 analysts
Ours vs. the Street +19.3% Our target vs. consensus

Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. Recalculated at least weekly and after every earnings report.

How we calculate it →
12-Month Projection Historical Optimistic Target Conservative
$14$21$28$35Nov 2025Nov 2027Nov 2$37.60$31.32$25.36
$14$21$28$35Nov 2025Nov 2027Nov 2$37.60$31.32$25.36

Analyst Sentiment

20ANALYSTS
Buy1050%
Hold1050%
Sell00%
The Bottom Line

Ultragenyx appears attractively valued at current levels. With a 94.5% upside to our $31.32 target, the risk-reward profile looks favorable for investors with a 12-month time horizon. Wall Street agrees, with 50% of analysts rating it a Buy.

The 24/7 Factor

Base Growth
Conservative growth baseline (reduced to avoid double-counting P/E growth)
1.05×
Sector Momentum
Defensive growth with aging population tailwinds
1.10×
Analyst Consensus
Moderate analyst optimism
+3.0%
Volatility Adjustment
Lower volatility stock
+1.3%
Read our full methodology →

5-Year Projection

Long-Term Forecast Optimistic Target Conservative
$30$60$90$120’26’27’28’29’30’31$117.61$98.91$45.84
$30$60$90$120’26’27’28’29’30’31$117.61$98.91$45.84

Prediction History

RARE Price Target History Our Target Stock Price
$20$40$60Aug 7Oct 30$31.32$16.10
$20$40$60Aug 7Oct 30$31.32$16.10
Date Price Target Stock Price Rating Upside
$31.32 $16.10 BUY +94.5%
$32.89 $14.51 BUY +126.6%
$32.89 $14.30 BUY +130.0%
$32.86 $15.30 BUY +114.8%
$67.82 $25.61 BUY +164.8%
$66.79 $25.83 BUY +158.6%
$65.10 $26.49 BUY +145.8%
$65.10 $25.63 BUY +154.0%

Frequently Asked Questions

What is the RARE stock price prediction for 2030?

Looking ahead to 2030, our model projects RARE could trade at an average price of $68.80, with a potential range between $51.60 and $85.99. This represents a potential 327.3% return from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.

Is RARE a buy, sell, or hold right now?

24/7 Wall St. currently rates RARE as a BUY. Strong upside (+94.5%) Among Wall Street analysts, 10 rate it Buy, 10 rate it Hold, and 0 rate it Sell.

What is the RARE stock price target in an optimistic scenario?

In our optimistic scenario for RARE, the stock could reach $37.60 over the next 12 months, representing a 133.5% gain from today’s price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company initiatives.

What is the downside risk for RARE stock?

Our conservative scenario for RARE projects a price of $25.36 over the next 12 months (57.5% from current levels), suggesting relatively limited downside if headwinds materialize. No forecast is a guarantee. Position sizing and time horizon still matter.

Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →